Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs

A. Galgani, C. Palleria, L. F. Iannone, G. De Sarro, F. S. Giorgi, M. Maschio, E. Russo

Research output: Contribution to journalArticle

Abstract

Direct oral anticoagulants (DOACs), namely apixaban, dabigatran, edoxaban, and rivaroxaban are being increasingly prescribed among the general population, as they are considered to be associated to lower bleeding risk than classical anticoagulants, and do not require coagulation monitoring. Likewise, DOACs are increasingly concomitantly prescribed in patients with epilepsy taking, therefore, antiepileptic drugs (AEDs), above all among the elderly. As a result, potential interactions may cause an increased risk of DOAC-related bleeding or a reduced antithrombotic efficacy. The objective of the present review is to describe the pharmacokinetic interactions between AEDs and DOACs of clinical relevance. We observed that there are only few clinical reports in which such interactions have been described in patients. More data are available on the pharmacokinetics of both drugs classes which allow speculating on their potential interactions. Older AEDs, acting on cytochrome P450 isoenzymes, and especially on CYP3A4, such as phenobarbital, phenytoin, and carbamazepine are more likely to significantly reduce the anticoagulant effect of DOACs (especially rivaroxaban, apixaban, and edoxaban). Newer AEDs not affecting significantly CYP or P-gp, such as lamotrigine, or pregabalin are not likely to affect DOACs efficacy. Zonisamide and lacosamide, which do not affect significantly CYP activity in vitro, might have a quite safe profile, even though their effects on P-gp are not well-known, yet. Levetiracetam exerts only a potential effect on P-gp activity, and thus it might be safe, as well. In conclusion, there are only few case reports and limited evidence on interactions between DOACs and AEDs in patients. However, the overall evidence suggests that the interaction between these drug classes might be of high clinical relevance and therefore further studies in larger patients' cohorts are warranted for the future in order to better clarify their pharmacokinetic and define the most appropriate clinical behavior.
Original languageEnglish
Pages (from-to)1067
Number of pages1
JournalFrontiers in Neurology
Volume9
DOIs
Publication statusPublished - Dec 7 2018

Fingerprint

Anticonvulsants
Anticoagulants
Pharmacokinetics
zonisamide
etiracetam
Hemorrhage
Cytochrome P-450 CYP3A
Carbamazepine
Phenytoin
Phenobarbital
Drug Interactions
Cytochrome P-450 Enzyme System
Isoenzymes
Epilepsy
Pharmaceutical Preparations
Population

Keywords

  • AEDs
  • CYP
  • DOACs
  • P-gp
  • antiepileptics
  • dabigatran
  • interactions
  • rivaroxaban

Cite this

Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. / Galgani, A.; Palleria, C.; Iannone, L. F.; Sarro, G. De; Giorgi, F. S.; Maschio, M.; Russo, E.

In: Frontiers in Neurology, Vol. 9, 07.12.2018, p. 1067.

Research output: Contribution to journalArticle

Galgani, A. ; Palleria, C. ; Iannone, L. F. ; Sarro, G. De ; Giorgi, F. S. ; Maschio, M. ; Russo, E. / Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. In: Frontiers in Neurology. 2018 ; Vol. 9. pp. 1067.
@article{a18b4198b2904857ae556fa792f74c40,
title = "Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs",
abstract = "Direct oral anticoagulants (DOACs), namely apixaban, dabigatran, edoxaban, and rivaroxaban are being increasingly prescribed among the general population, as they are considered to be associated to lower bleeding risk than classical anticoagulants, and do not require coagulation monitoring. Likewise, DOACs are increasingly concomitantly prescribed in patients with epilepsy taking, therefore, antiepileptic drugs (AEDs), above all among the elderly. As a result, potential interactions may cause an increased risk of DOAC-related bleeding or a reduced antithrombotic efficacy. The objective of the present review is to describe the pharmacokinetic interactions between AEDs and DOACs of clinical relevance. We observed that there are only few clinical reports in which such interactions have been described in patients. More data are available on the pharmacokinetics of both drugs classes which allow speculating on their potential interactions. Older AEDs, acting on cytochrome P450 isoenzymes, and especially on CYP3A4, such as phenobarbital, phenytoin, and carbamazepine are more likely to significantly reduce the anticoagulant effect of DOACs (especially rivaroxaban, apixaban, and edoxaban). Newer AEDs not affecting significantly CYP or P-gp, such as lamotrigine, or pregabalin are not likely to affect DOACs efficacy. Zonisamide and lacosamide, which do not affect significantly CYP activity in vitro, might have a quite safe profile, even though their effects on P-gp are not well-known, yet. Levetiracetam exerts only a potential effect on P-gp activity, and thus it might be safe, as well. In conclusion, there are only few case reports and limited evidence on interactions between DOACs and AEDs in patients. However, the overall evidence suggests that the interaction between these drug classes might be of high clinical relevance and therefore further studies in larger patients' cohorts are warranted for the future in order to better clarify their pharmacokinetic and define the most appropriate clinical behavior.",
keywords = "AEDs, CYP, DOACs, P-gp, antiepileptics, dabigatran, interactions, rivaroxaban",
author = "A. Galgani and C. Palleria and Iannone, {L. F.} and Sarro, {G. De} and Giorgi, {F. S.} and M. Maschio and E. Russo",
note = "LR: 20181226; JID: 101546899; OTO: NOTNLM; 2018/08/08 00:00 [received]; 2018/11/23 00:00 [accepted]; 2018/12/25 06:00 [entrez]; 2018/12/26 06:00 [pubmed]; 2018/12/26 06:01 [medline]; epublish",
year = "2018",
month = "12",
day = "7",
doi = "10.3389/fneur.2018.01067 [doi]",
language = "English",
volume = "9",
pages = "1067",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs

AU - Galgani, A.

AU - Palleria, C.

AU - Iannone, L. F.

AU - Sarro, G. De

AU - Giorgi, F. S.

AU - Maschio, M.

AU - Russo, E.

N1 - LR: 20181226; JID: 101546899; OTO: NOTNLM; 2018/08/08 00:00 [received]; 2018/11/23 00:00 [accepted]; 2018/12/25 06:00 [entrez]; 2018/12/26 06:00 [pubmed]; 2018/12/26 06:01 [medline]; epublish

PY - 2018/12/7

Y1 - 2018/12/7

N2 - Direct oral anticoagulants (DOACs), namely apixaban, dabigatran, edoxaban, and rivaroxaban are being increasingly prescribed among the general population, as they are considered to be associated to lower bleeding risk than classical anticoagulants, and do not require coagulation monitoring. Likewise, DOACs are increasingly concomitantly prescribed in patients with epilepsy taking, therefore, antiepileptic drugs (AEDs), above all among the elderly. As a result, potential interactions may cause an increased risk of DOAC-related bleeding or a reduced antithrombotic efficacy. The objective of the present review is to describe the pharmacokinetic interactions between AEDs and DOACs of clinical relevance. We observed that there are only few clinical reports in which such interactions have been described in patients. More data are available on the pharmacokinetics of both drugs classes which allow speculating on their potential interactions. Older AEDs, acting on cytochrome P450 isoenzymes, and especially on CYP3A4, such as phenobarbital, phenytoin, and carbamazepine are more likely to significantly reduce the anticoagulant effect of DOACs (especially rivaroxaban, apixaban, and edoxaban). Newer AEDs not affecting significantly CYP or P-gp, such as lamotrigine, or pregabalin are not likely to affect DOACs efficacy. Zonisamide and lacosamide, which do not affect significantly CYP activity in vitro, might have a quite safe profile, even though their effects on P-gp are not well-known, yet. Levetiracetam exerts only a potential effect on P-gp activity, and thus it might be safe, as well. In conclusion, there are only few case reports and limited evidence on interactions between DOACs and AEDs in patients. However, the overall evidence suggests that the interaction between these drug classes might be of high clinical relevance and therefore further studies in larger patients' cohorts are warranted for the future in order to better clarify their pharmacokinetic and define the most appropriate clinical behavior.

AB - Direct oral anticoagulants (DOACs), namely apixaban, dabigatran, edoxaban, and rivaroxaban are being increasingly prescribed among the general population, as they are considered to be associated to lower bleeding risk than classical anticoagulants, and do not require coagulation monitoring. Likewise, DOACs are increasingly concomitantly prescribed in patients with epilepsy taking, therefore, antiepileptic drugs (AEDs), above all among the elderly. As a result, potential interactions may cause an increased risk of DOAC-related bleeding or a reduced antithrombotic efficacy. The objective of the present review is to describe the pharmacokinetic interactions between AEDs and DOACs of clinical relevance. We observed that there are only few clinical reports in which such interactions have been described in patients. More data are available on the pharmacokinetics of both drugs classes which allow speculating on their potential interactions. Older AEDs, acting on cytochrome P450 isoenzymes, and especially on CYP3A4, such as phenobarbital, phenytoin, and carbamazepine are more likely to significantly reduce the anticoagulant effect of DOACs (especially rivaroxaban, apixaban, and edoxaban). Newer AEDs not affecting significantly CYP or P-gp, such as lamotrigine, or pregabalin are not likely to affect DOACs efficacy. Zonisamide and lacosamide, which do not affect significantly CYP activity in vitro, might have a quite safe profile, even though their effects on P-gp are not well-known, yet. Levetiracetam exerts only a potential effect on P-gp activity, and thus it might be safe, as well. In conclusion, there are only few case reports and limited evidence on interactions between DOACs and AEDs in patients. However, the overall evidence suggests that the interaction between these drug classes might be of high clinical relevance and therefore further studies in larger patients' cohorts are warranted for the future in order to better clarify their pharmacokinetic and define the most appropriate clinical behavior.

KW - AEDs

KW - CYP

KW - DOACs

KW - P-gp

KW - antiepileptics

KW - dabigatran

KW - interactions

KW - rivaroxaban

U2 - 10.3389/fneur.2018.01067 [doi]

DO - 10.3389/fneur.2018.01067 [doi]

M3 - Article

VL - 9

SP - 1067

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

ER -